Skip to main navigation
Skip to search
Skip to main content
UNT Health Home
Search content at UNT Health
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
The many faces of innate immunity in SARS-CoV-2 infection
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The many faces of innate immunity in SARS-CoV-2 infection'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Innate Immunity
100%
Innate Immune Response
100%
SARS-CoV-2 Infection
100%
Interleukin-6
66%
Interleukin-8
66%
COVID-19
66%
Overactivity
66%
Lymphopenia
66%
Neutrophils
33%
Therapeutic Efficacy
33%
Lymphocyte Subsets
33%
Genetic Risk
33%
Poor Outcome
33%
Prominent Features
33%
Cytokine Storm
33%
Acute Respiratory Distress Syndrome
33%
Neutrophil Extracellular Traps
33%
COVID-19 Patients
33%
Dysregulated Immune Response
33%
Host Inflammatory Response
33%
Pre-existing Comorbidity
33%
Viral Pathogenicity
33%
Severe COVID-19 Patients
33%
Neutrophilia
33%
Antiviral Response
33%
Neutrophil-to-lymphocyte Ratio
33%
Viral Therapeutics
33%
Lung Tissue Damage
33%
Medicine and Dentistry
Infection
100%
Innate Immunity
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Neutrophil
75%
Interleukin 6
50%
COVID-19
50%
Interleukin 8
50%
Lymphocytopenia
50%
Immune Response
25%
Serositis
25%
Lymphocyte Subpopulation
25%
Combination Therapy
25%
Tissue Injury
25%
Antivirus Agent
25%
Cytokine Storm
25%
Genetic Risk
25%
Extracellular Trap
25%
Virus Virulence
25%
Neutrophilia
25%
Acute Respiratory Distress Syndrome
25%
Lung
25%
Comorbidity
25%
Lymphocyte
25%
Diseases
25%
Immunology and Microbiology
Innate Immune System
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Infection
100%
Neutrophil
50%
Interleukin 6
50%
COVID-19
50%
Lymphocytopenia
50%
Interleukin 8
50%
Immune Response
25%
Inflammation Response
25%
Genetic Risk
25%
Lymphocyte Subpopulation
25%
Cytokine Storm
25%
Neutrophil Extracellular Traps
25%
Virus Virulence
25%
Lymphocyte
25%
Comorbidity
25%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
SARS Coronavirus
100%
Interleukin 6
50%
Interleukin 8
50%
Lymphocytopenia
50%
Inflammation
25%
Combination Therapy
25%
Antivirus Agent
25%
Tissue Injury
25%
Genetic Risk
25%
Cytokine Storm
25%
Adult Respiratory Distress Syndrome
25%
Neutrophilia
25%
Virus Virulence
25%
Comorbidity
25%
Diseases
25%